INSTITUT CURIE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1909-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.curie.fr
First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide)
Early Phase 1
Recruiting
- Conditions
- Metastatic Solid Tumor Cancer
- Interventions
- Combination Product: Dose escalation, first-in-human phase I clinical trial with an Expansion phase
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 101
- Registration Number
- NCT04733027
- Locations
- 🇫🇷
CLCC F.Baclesse Caen, Caen, France
🇫🇷Institut Curie, Paris, France
🇫🇷Institut de Cancerologie de l'Ouest- ICO, Saint-Herblain, France
Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma
Not Applicable
Recruiting
- Conditions
- Thymoma Malignant Recurrent
- Interventions
- Other: RadiotherapyOther: Surveillance after resection
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 314
- Registration Number
- NCT04731610
- Locations
- 🇫🇷
Hôpital Européen Georges Pompidou, Paris, France
🇫🇷CHU Haut Lévêque, Pessac, France
🇫🇷CHU Caen, Caen, France
Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)
Not Applicable
Completed
- Conditions
- Uveal Melanoma
- Interventions
- Other: Supportive care visit with questionnairesOther: Oncological standard visit
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 162
- Registration Number
- NCT04728113
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇫🇷Institut Curie, Paris, France
Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- HER2-negative Metastatic Breast Cancer
- Interventions
- Biological: Chemotherapy monitoring by circulating tumor DNA analysis
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 160
- Registration Number
- NCT04720729
- Locations
- 🇫🇷
Institut Curie, Paris, France
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
Phase 2
Recruiting
- Conditions
- Retinoblastoma
- Interventions
- Drug: etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapyDevice: Cryotherapy (local treatment)Device: Thermotherapy (local treatment)Device: Iodine-125 plaques (local treatment)Drug: Intravitreal Melphalan chemotherapy injections (local treatment)
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 225
- Registration Number
- NCT04681417
- Locations
- 🇫🇷
La Reunion - Chr Felix Guyon, Saint-Denis, La Réunion, France
🇫🇷Amiens Chu, Amiens, France
🇫🇷Angers Chu, Angers, France
DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI)
Not Applicable
Recruiting
- Conditions
- Cancer Patients With Cancer Pain
- Interventions
- Other: Experimental groupOther: standrad group
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 270
- Registration Number
- NCT04634097
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest Paul Papin, Angers, France
🇫🇷Institut Curie, Saint-cloud, France
🇫🇷GH Diaconesses Croix Saint Simon (GHDCSS), Paris, France
The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers (HDJ-SPI)
Not Applicable
Active, not recruiting
- Conditions
- Cancer, Advanced
- Interventions
- Other: Hospital day care follow-up
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 144
- Registration Number
- NCT04604873
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Institutcurie Paris, Paris, France
Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer.
Not Applicable
Completed
- Conditions
- SurgeryBreast Cancer
- Interventions
- Diagnostic Test: Sorbstar®Diagnostic Test: Dog Detection
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 35
- Registration Number
- NCT04541537
- Locations
- 🇫🇷
Institut Curie, Paris, France
Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive Oncology
Not Applicable
Completed
- Conditions
- Non-colorectal Cancer (Esophagus, Stomach, Liver/Bile Ducts, Pancreas, Neuroendocrine Carcinoma)Colorectal With Associated Risk Factors
- Interventions
- Other: multidisciplinary assessment and intervention
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 30
- Registration Number
- NCT04478175
- Locations
- 🇫🇷
Institut Curie, Paris, France
Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer
Not Applicable
Terminated
- Conditions
- Breast CancerSurgery
- Interventions
- Other: Coaching sessions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 69
- Registration Number
- NCT04469205
- Locations
- 🇫🇷
Institut Curie, Saint-Cloud, France